Papillary carcinomas of thyroid generally have an indolent course with metastatic disease in less than 5% of patients. Common sites of distant metastasis include lung and bone. A presentation with malignant pleural effusion is exceedingly rare with only a handful of cases reported in literature. We present a case and discuss the treatment of a patient presenting of papillary thyroid cancer with a relapse of the disease in the pleural cavity. There are no standard treatment recommendations in this setting in view of paucity of published data from literature.
INTRODUCTION
Papillary thyroid carcinoma usually metastasizes to the neck nodes, lung and bone but relapsing as a pleural effusion is rare. It is found in only 0.6% of patients as reported in a large case series over a period of 47 years. 2 Only approximately 4 to 15% of patients presented initially with distant metastasis in well-differentiated thyroid cancer. 3, 8, 9 We present a case report of one of our patients presenting as a malignant pleural effusion from papillary carcinoma thyroid. Metastatic pleural effusion as the initial manifestation in papillary thyroid cancer is reported very rarely.
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CASE REPORT
A 52-year-old gentleman, a chronic smoker with hypertension and ischemic heart disease on medication, presented to us in January 2006 with a thyroid swelling and right sided cervical lymphadenopathy. He was diagnosed to have papillary carcinoma thyroid. He underwent a total thyroidectomy, bilateral paratracheal lymph node dissection and right side modified radical neck dissection then. consistent with metastatic papillary thyroid carcinoma. His serum thyroglobulin was 54.3 ng/ml, an Iodine 131 uptake scan was 0.3% and whole body scan was negative. In view of nonfunctioning metastasis, radio-iodine therapy was not considered. A tetracycline pleurodesis was done (Fig. 2) . The patient was not inclined to consider any other treatment options (chemotherapy/targeted therapy), there being no standard recommendations and is following up with us on eltroxin suppression.
DISCUSSION
Malignant pleural effusions are caused most commonly by carcinomas of the breast, lung, gastrointestinal tract, ovary and lymphoid malignancies. In male patients about half of malignant effusions are caused by lung cancer, 20% by lymphomas or leukemia, 7% from gastrointestinal primaries, 6% from genitourinary primaries, and 11% from tumors of unknown primary site. In female patients, about 40% of malignant effusions are caused by breast cancer, 20% from tumors arising in the female genital tract, 15% from lung primaries, 8% from lymphomas or leukemia, 4% from gastrointestinal tract primaries, 3% from melanoma, and 9% from tumors of unknown primary site. 1 Papillary carcinomas of thyroid generally have an indolent course with metastatic disease in less than 5% of patients. Common sites of distant metastasis include lung (67%) and bone (25%). A presentation with malignant pleural effusion is exceedingly rare. Immunohistochemistry with TTF-1 and thyroglobulin on cytology helps to differentiate metastatic adenocarcinoma lung from thyroid where in serum thyroglobulin is normal. 7 Typically, the presence of a malignant pleural effusion portends a dismal prognosis, with a reported median survival of 11 months. 2, 4 Metastatic pleural effusion commonly seen in papillary carcinoma thyroid except one case report of hurtle cell carcinoma (Figs 3 and 4 ).
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CONCLUSION
Malignant pleural effusion from a papillary carcinoma is an exceedingly rare differential diagnosis even in the background of thyroid malignancy. In view of paucity of data there are no standard treatment recommendations. 
